Dr. Spigel observed that no new safety concerns emerged in the trial, although patients treated with MetMAb had more peripheral edema that was largely low grade, reversible, and manageable.
A phase III study testing MetMAb plus erlotinib in Met diagnostic–positive patients is expected to start enrolling this year, he said.
Dr. Spigel disclosed a consultant/advisory role with Genentech, which sponsored the study. His coauthors disclosed financial relationships with several firms including employment with Genentech.